share_log

Grail | 8-K: GRAIL Reports Third Quarter 2024 Financial Results

Grail | 8-K: GRAIL Reports Third Quarter 2024 Financial Results

Grail | 8-K:GRAIL 公佈2024年第三季度財務業績
美股SEC公告 ·  2024/11/13 05:05

Moomoo AI 已提取核心訊息

Grail reported Q3 2024 total revenue of $28.7M, up 38% YoY, with Galleri screening revenue growing 52% to $25.4M. The company's net loss narrowed to $125.7M, including $34.6M in acquisition-related amortization and a $19M restructuring charge. Gross loss was $22.2M, while adjusted gross profit reached $11.8M.The company achieved a significant milestone with over 250,000 Galleri tests sold since launch. Recent clinical data showed promising results, with the REFLECTION study at VA sites demonstrating a 1.3% signal detection rate and 42.9% positive predictive value, with over half of cases identified at early stages.Grail maintained a strong financial position with $853.6M in cash, providing runway into 2028. The company continues to focus on cost management while advancing its registrational studies for FDA PMA submission and pursuing broad reimbursement coverage.
Grail reported Q3 2024 total revenue of $28.7M, up 38% YoY, with Galleri screening revenue growing 52% to $25.4M. The company's net loss narrowed to $125.7M, including $34.6M in acquisition-related amortization and a $19M restructuring charge. Gross loss was $22.2M, while adjusted gross profit reached $11.8M.The company achieved a significant milestone with over 250,000 Galleri tests sold since launch. Recent clinical data showed promising results, with the REFLECTION study at VA sites demonstrating a 1.3% signal detection rate and 42.9% positive predictive value, with over half of cases identified at early stages.Grail maintained a strong financial position with $853.6M in cash, providing runway into 2028. The company continues to focus on cost management while advancing its registrational studies for FDA PMA submission and pursuing broad reimbursement coverage.
Grail報告2024年第三季度總營業收入爲2870萬美元,同比增長38%,Galleri篩查收入增長52%至2540萬美元。公司的淨虧損縮小至12570萬美元,其中包括3460萬美元的收購相關攤銷和1900萬美元的重組費用。毛虧損爲2220萬美元,而調整後的毛利潤達到1180萬美元。該公司實現了一個重要里程碑,自推出以來銷售超過250,000個Galleri測試。近期的臨牀數據表明了前景樂觀,VA機構的REFLECTION研究顯示信號檢測率爲1.3%,陽性預測值爲42.9%,超過一半的病例在早期階段被識別。Grail保持強勁的財務狀況,現金達到85360萬美元,資金充足可延續到2028年。該公司繼續專注於成本管理,同時推進其註冊研究,以便向FDA提交PMA申請並尋求廣泛的報銷覆蓋。
Grail報告2024年第三季度總營業收入爲2870萬美元,同比增長38%,Galleri篩查收入增長52%至2540萬美元。公司的淨虧損縮小至12570萬美元,其中包括3460萬美元的收購相關攤銷和1900萬美元的重組費用。毛虧損爲2220萬美元,而調整後的毛利潤達到1180萬美元。該公司實現了一個重要里程碑,自推出以來銷售超過250,000個Galleri測試。近期的臨牀數據表明了前景樂觀,VA機構的REFLECTION研究顯示信號檢測率爲1.3%,陽性預測值爲42.9%,超過一半的病例在早期階段被識別。Grail保持強勁的財務狀況,現金達到85360萬美元,資金充足可延續到2028年。該公司繼續專注於成本管理,同時推進其註冊研究,以便向FDA提交PMA申請並尋求廣泛的報銷覆蓋。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息